Loading...
XSHG
603811
Market cap499mUSD
Dec 05, Last price  
10.94CNY
1D
1.11%
1Q
-24.19%
IPO
68.31%
Name

Zhejiang Cheng Yi Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603811 chart
P/E
17.60
P/S
4.95
EPS
0.62
Div Yield, %
1.83%
Shrs. gr., 5y
0.10%
Rev. gr., 5y
0.95%
Revenues
714m
+6.36%
215,280,625255,433,213266,056,314320,232,009316,953,907321,223,084340,892,105545,765,999681,227,988758,132,059693,964,770654,972,841671,626,943714,369,070
Net income
201m
+23.21%
13,350,70529,301,43836,497,63553,853,78857,705,08168,169,23869,238,44596,911,570131,391,821165,143,823170,797,181161,583,203162,896,651200,700,773
CFO
206m
+5.61%
10,041,20037,958,50048,186,70084,108,70981,942,63795,079,58166,750,889134,298,067181,013,149177,805,369143,488,423165,937,267194,780,877205,715,849
Dividend
Jun 11, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs and capsules/tablets in China. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966 and is headquartered in Wenzhou, China.
IPO date
Mar 15, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT